Siltuximab is a monoclonal antibody that specifically targets interleukin-6 (IL-6), a cytokine involved in inflammatory responses and immune regulation. It is primarily used in the treatment of certain conditions associated with excessive IL-6 production, such as multicentric Castleman’s disease, a rare lymphoproliferative disorder. Siltuximab works by binding to IL-6, inhibiting its interaction with the IL-6 receptor, and thereby reducing the inflammatory effects mediated by this cytokine. The molecular structure of siltuximab is characterized by its large protein size, typical of monoclonal antibodies, which allows for high specificity and affinity for its target. It is administered via intravenous infusion, and its pharmacokinetics can be influenced by factors such as the patient's body weight and the presence of other medical conditions. Common side effects may include infusion-related reactions, infections, and changes in blood cell counts. Overall, siltuximab represents a targeted therapeutic approach in managing diseases driven by IL-6 dysregulation.

Siltuximab

541502-14-1: Siltuximab is a monoclonal antibody that specifically targets interleukin-6 (IL-6), a cytokine involved in inflammatory responses and immune regulation. It is primarily used in the treatment of certain conditions associated with excessive IL-6 production, such as multicentric Castleman’s disease, a rare lymphoproliferative disorder. Siltuximab works by binding to IL-6, inhibiting its interaction with the IL-6 receptor, and thereby reducing the inflammatory effects mediated by this cytokine. The molecular structure of siltuximab is characterized by its large protein size, typical of monoclonal antibodies, which allows for high specificity and affinity for its target. It is administered via intravenous infusion, and its pharmacokinetics can be influenced by factors such as the patient's body weight and the presence of other medical conditions. Common side effects may include infusion-related reactions, infections, and changes in blood cell counts. Overall, siltuximab represents a targeted therapeutic approach in managing diseases driven by IL-6 dysregulation.

<p>Siltuximab（CNTO-328） is a monoclonal antibody with anti-tumor activity targeting IL-6 for the study of giant lymph node hyperplasia (MCD) and COVID-19.</p>

<p>Anti-Human IL-6 Monoclonal Antibody</p>

CAS 541502-14-1

Siltuximab

Siltuximab

Ref: TM-T76978

Siltuximab

Ref: 3D-CLA1039